Search This Blog


Thursday, 8 April 2010

Market for Tbc medications

GIA announces the release of a comprehensive global report on Tuberculosis (TB) Therapeutics markets. Global tuberculosis therapeutics market is expected to exceed US$846 million by 2015. Outbreak of TB-HIV co-infections, emergence of MDR- and XDR- TB strains, and widespread disease prevalence in high burden regions such as Africa and Asia, where case detection rates are critically low posing significant challenge for the control of this disease, all indicate high unmet needs in diagnosis and treatment. The scenario presents excellent commercial opportunity for existing as well as new companies in this marketplace.

While modern medicine has rendered this highly contagious, and life-threatening disease curable, and treatable, the disease continues to challenge the medical community even to the present day. As the bacterium causing TB continues to evolve, mutate, and develop resistance against modern drugs, there exists an urgent and dire need to develop newer next generation drugs to fight the disease. The growing prevalence of XDR (extensively drug resistant) TB and MDR (multi-drug resistant) TB strains has created the need for newer diagnostics tools, and drugs to manage and control tuberculosis. R&D in this area confronts its toughest challenge ever, with global investments, and R& D funding on total TB research still continuing to fall short of requirements. The uncertainties over the level of the US government's contribution towards the Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) has also taken its toll on research funding, leading to funding deficits. This shortfall in funds has knifed the availability of finances in high-burden regions, such as the Sub-Saharan region.

No comments: